Hypoxia-inducible factor 1a (HIF-1a) is frequently overexpressed in human cancers and controls the expression of several genes that have been implicated in tumor growth and progression. Activity of HIF-1a in cancer cells is regulated at the transcriptional, translational and posttranslational level by multiple inter-and coacting molecular pathways. In this report, we reveal for the first time that tumor-associated CpG demethylation facilitates positive autoregulation of HIF-1a, resulting in amplification of hypoxia-induced transactivation of HIF-1a target genes. The HIF-1a promoter harbors a hypoxia response element that is normally repressed by methylation of a CpG dinucleotide located in the core element. In colon cancer cell lines and in primary colon cancer specimens, however, we found frequent aberrant demethylation of this element, enabling binding of HIF-1a to its own promoter resulting in autotransactivation of HIF-1a expression. Our results provide novel and highly unexpected insights into the complexity of HIF-1a regulation in cancer cells and implicate that tumor-associated CpG demethylation augments HIF-1a-mediated effects on malignant cell growth.
Introduction
Hypoxia-inducible factor 1a (HIF-1a) is a master regulator of the adaptive cellular response to hypoxia. Under normoxic conditions, HIF-1a is maintained at very low levels in most cells. The repression of HIF-1a results from the activity of oxygen-dependent prolyl hydroxylases (Bruick and McKnight, 2001 ). Hydroxylation of HIF-1a is required for the binding of the von Hippel-Lindau tumor suppressor protein (Jaakkola et al., 2001; Yu et al., 2001) , which is the recognition component of an E3 ubiquitin protein ligase that targets HIF-1a for proteosomal degradation (Maxwell et al., 1999; Ohh et al., 2000) . Under hypoxic conditions, oxygen becomes rate limiting for prolyl hydroxylation, resulting in decreased ubiquination of HIF-1a and accumulation of the protein. After heterodimerization with the constitutively expressed aryl hydrocarbon receptor nuclear translocator (ARNT/HIF-1b) HIF-1a binds to hypoxia response elements (HREs) in the promoter of target genes and mediates transcriptional transactivation of these genes (Wang and Semenza, 1993a, b) .
In solid tumors, HIF-1a is frequently overexpressed. The transactivation of HIF-1a targets, such as tumor growth promoting proangiogenic vascular endothelial growth factor, provides a distinctive survival advantage for malignant cells. Accordingly, upregulation of HIF1a correlates with progression, aggressiveness and poor prognosis in many cancer types (Semenza, 2010) . In cancer cells, HIF-1a can also be activated in an oxygen-independent manner by genetic loss of tumor suppressor genes like von Hippel-Lindau tumor suppressor protein and PTEN (Iliopoulos et al., 1996; Zundel et al., 2000) , and by oncogenic pathways such as receptor-mediated PI3K/AKT or mitogen-activated protein kinase signaling (Bilton and Booker, 2003) . As a consequence, cancer cells display increased HIF-1a protein levels even under normoxic conditions. Moreover, phosphoinositide 3-kinase/AKT and mitogenactivated protein kinase pathways cooperate with low oxygen tension to further enhance the induction of HIF1a activity in cancer cells (Mazure et al., 1997; Conrad et al., 1999; Zundel et al., 2000) . Thus, activation of HIF-1a in cancer cells is complex and not yet fully elucidated at the molecular level.
Our group studies the molecular mechanisms of regulating genes that are selectively activated in cancer (Koslowski et al., 2004 (Koslowski et al., , 2009a Sahin et al., 2008) . In the course of these investigations we observed that the hypoxic transcriptional response of known HIF-1a target genes is significantly enhanced in cells with a reduced CpG methylation state. This report details our efforts to identify the molecular basis underlying this effect.
Results and discussion
To analyze the combined effects of CpG demethylation and hypoxia, we quantified transcript levels of HIF-1a and its known target genes vascular endothelial growth factor, glucose transporter 1, lactate dehydrogenase A, aldolase A and transforming growth factor-b3 by realtime RT-PCR in peripheral blood mononuclear cells and the colon cancer cell line HCT-116. Hypoxia (1% O 2 ) for 12 h was sufficient to induce all target genes, whereas transcription of HIF-1a remained unaffected (Figure 1a ). Most interestingly, in hypoxic cells, treated with the DNA demethylating agent 5-aza-2 0 -deoxycytidine (5-aza-dC), a dose-dependent augmentation of transcript levels of all the tested HIF-1a target genes was observed, and in contrast to untreated cells HIF-1a expression also was strongly induced. Importantly, basal expression levels of all the genes were not affected by 5-aza-dC treatment in cells cultured under normoxic conditions. These observations were confirmed on the protein level by western blot analysis. Vascular endothelial growth factor protein was barely detectable in normoxic cells, but was clearly induced after exposure to hypoxia (Figure 1b ). Reflecting our RT-PCR data, 5-aza-dC treatment resulted in dose-dependent increase of vascular endothelial growth factor in hypoxic but not in normoxic cells. We did not observe HIF-1a protein in normoxic cells, whereas it was robustly detected on exposure to hypoxia. As HIF-1a transcription was not induced by hypoxia (Figure 1a ), this finding implied stabilization of HIF-1a protein by decreased proteosomal degradation (Maxwell et al., 1999; Ohh et al., 2000) . 5-aza-dC treatment further augmented HIF-1a protein levels in hypoxic cells, most likely as a combined effect of decreased proteosomal degradation and enhanced transcription (Figure 1b) . It is well known that several hypoxia response genes are targets for both HIF-1a and its homolog HIF-2a (Ema et al., 1997; HolmquistMengelbier et al., 2006; Lofstedt et al., 2007) . Stabilization of HIF-2a protein, however, which we found in hypoxic HCT-116 cells but not in primary PBMCs, was not affected by 5-aza-dC treatment (Figure 1b) . The dominant role of HIF-1a in demethylation-mediated augmentation of the hypoxic response was further Figure 1 5-aza-dC treatment of cells increases hypoxia-induced gene expression. (a) mRNA expression of HIF-1a, VEGF, GLUT1, LDHA, ALDOA and TGFB3 was quantified using real time RT-PCR after 12 h exposure to hypoxia (1% O 2 ). HCT-116 colon carcinoma cells were cultured in McCoy's 5A modified medium with 10% fetal calf serum. PBMCs were isolated from buffy coats by density gradient centrifugation using Ficoll-Paque (PAA, Pasching, Austria) and cultured in RPMI 1640 with 10% fetal calf serum. To induce genomic DNA, demethylation cells were culture in medium supplemented with 2 or 10 mM 5-aza-2 0 -deoxycytidine (Sigma, St Louis, MO, USA) for 72 h, respectively. RNA extraction, first-strand cDNA synthesis and real time RT-PCR were performed as previously described (Koslowski et al., 2006) . Real-time quantitative expression analysis was performed in triplicates in a 40-cycle RT-PCR. After normalization to HPRT (forward 5 0 -TGACACTGGCAAAACAATGCA-3 0 ; reverse 5
0 -GTGGCTGTTGAGAAGAGAGTC-3 0 , reverse 5 0 -CTCCCAACATAGTACAGGCTG-3 0 ; 651C) and HIF-1a (forward 5 0 -TACTAGCTTTGCAGAATGCTC-3 0 , reverse 5 0 -GCCTTGTATAGGAGCATTAAC-3 0 ; 601C) was quantified using DDCt calculation. Expression of each gene is shown in relation to expression levels in untreated control cells cultured at 21% O 2 . All assays were done in triplicates; mean values ± s.d. are shown. (b) Protein expression of VEGF, HIF-1a, HIF-2a and b-actin was analyzed by western blot in lysates of cells treated under same conditions as in (a). Whole-cell lysates were prepared using RIPA lysis buffer. Extracts were diluted in reducing sample buffer (Roth), subjected to SDS-PAGE and subsequently blotted onto PVDF membrane (Pall, Port Washington, NY, USA). Immunostaining was performed with antibodies reactive to VEGF, HIF-1a, HIF-2a and b-actin (all from Abcam, Cambridge, UK), followed by detection of primary antibodies with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA).
HIF-1a autoregulation M Koslowski et al supported in 5-aza-dC-treated cells after transfection with small interfering RNA oligos specifically targeting HIF-1a transcripts (Supplementary Figure 1) . Silencing of HIF-1a expression in these cells completely or nearly completely abolished HIF-1a autoregulation and transactivation of all hypoxia response genes analyzed.
These findings suggested that hypoxic induction of HIF-1a transcription might be under governance of regulatory cis-or trans-acting elements that become activated by CpG demthylation. Therefore, we analyzed the HIF-1a promoter region using the TFsearch program (http://www.cbrc.jp/research/db/TFSEARCH), TRANSFAC database (http://www.gene-regulation. com) and EMBOSS CpG plot program (http://www.ebi. ac.uk/Tools/emboss/cpgplot). On the basis of its size, GC content and CpG dinucleotide frequency, a CpG island was predicted from positions -271 to þ 96. At positions -156 to À152, a sequence resembling the consensus core HRE (5 0 -RCGTG-3 0 ) was identified ( Figure 2a) . By bisulfite sequencing of the promoter, we revealed lack of CpG methylation at positions from -115 to þ 96 and heavy methylation at positions from -271 to À139 in untreated cells (Figure 2b, left) . In both cell types, 5-aza-dC treatment resulted in progressive loss of CpG methylation at positions from -271 to À139, including the CpG dinucleotide (À155) located within the putative HRE. It is well known that methylation of CpG dinucleotides in DNA recognition elements can serve as 'molecular lock', blocking the binding of sequence-specific trans-acting proteins through both direct steric hindrance and recruitment of repressor proteins (Tate and Bird, 1993; Siegfried and Cedar, 1997) . Such a mechanism has been recently reported for HIF-1-mediated hypoxic induction of the glycoprotein hormone erythropoietin that stimulates erythrocyte production and maturation. CpG methylation in the HRE located in the proximal erythropoietin promoter prevents binding of HIF-1, thereby abolishing hypoxia-mediated induction of erythropoietin expression (Wenger et al., 1998; Yin and Blanchard, 2000) . We suspected that the hypoxic induction of HIF-1a transcription in 5-aza-dC-treated hypoxic cells might be governed likewise by differential methylation of the HRE CpG dinucleotide at position À155.
To test this hypothesis, we first established a methylationspecific quantitative PCR assay for quantification of CpG HIF-1a autoregulation M Koslowski et al methylation at the HRE site. Results of the methylationspecific quantitative PCR perfectly matched the bisulfite sequencing data (Figure 2b , right). To verify that the predicted element at positions from-156 to À152 indeed represents a functional HRE, luciferase reporter genes directed either by the wild-type HIF-1a promoter domain (À1163 to þ 117) or by a variant mutated in the putative HRE were expressed in peripheral blood mononuclear cells and HCT-116 cells. Hypoxic induction of the HIF-1a promoter activity was observed exclusively in cells transfected with the wild-type construct. Mutation of the predicted HRE completely abolished hypoxia-induced promoter activity in both the cell types (Figure 2c ). Targeting of HIF-1 to the HRE was further analyzed using an ELISA-based transcription factor binding assay as described previously (Koslowski et al., 2009a, b (Figure 2d ), indicating the binding of HIF-1 to the predicted HRE sequence. Mutation of the HRE sequence in the oligonucleotide capture probe (capture mut ) prevented binding of HIF-1. Moreover, complex formation was inhibited by excess amounts of nonbiotinylated capture wt probe as competitor (competitor wt ), but not by competitor probe with mutated binding site (competitor mut ), confirming specificity of this interaction. Most importantly, however, HIF-1 did not bind to a capture probe containing a methylated cytosine in the core HRE sequence (capture dCmet ). Chromatin immunoprecipitation with an HIF-1a-specific antibody confirmed that HIF-1 was not recruited to the endogenous HIF-1a promoter in untreated hypoxic cells, whereas increased recruitment was observed in 5-aza-dC-treated Figure 2 Hypoxic activation of the HIF-1a promoter is under control of a methylation-sensitive hypoxia response element (HRE).
(a) Proximal 5 0 -flanking region of the HIF-1a gene. The predicted core HRE is shown in gray, CpG dinucleotides are bold and transcription start is underlined. (b) CpG methylation of the HIF-1a promoter was analyzed by bisulfite sequencing and MSqPCR specific for the methylated HRE CpG dinucleotide in the HIF-1a promoter at position À155. DNA from cells was extracted using DNeasy Tissue Kit (Qiagen, Hilden, Germany) and subjected to bisulfite modification using the CpGenome DNA Modification Kit (Intergen, New York, NY, USA) according to the manufacturer's instructions as previously described (Koslowski et al., 2006) . In brief, 1 mg of genomic DNA was denatured by sodium hydroxide and then chemically modified by sodium bisulfite treatment for 20 h. This converts the unmethylated cytosine to uracil, whereas methylated cytosine remains unchanged. The modified DNA was recovered by ethanol precipitation and resuspended in PCR grade water. For mapping of methylated cytosine, residues' reaction products were amplified with primers specific for the modified HIF-1a promoter sequence. Amplification products were cloned into TA cloning vector (Invitrogen) and 10 individual clones of each product were sequenced. Filled circles, methylated CpG; open circles, unmethylated CpG. The methylation analysis was performed by fluorescence-based real time PCR assays as previously described (Koslowski et al., 2006) . Primers were designed to specifically amplify bisulfite-converted DNA of the methylated HRE located in the HIF-1a promoter (forward 5 0 -GAGTTTTTAGATTCGGGTTGAGTC-3 0 ; reverse 5 0 -GCACTCGCAGCATCAAGACAAA-3 0 ). Amplification of b-actin (ACTB) with primers (forward 5 0 -TGGTGATGGAGGAGGTTTAGTAAGT-3 0 ; reverse 5 0 -AACCAATAAAACC TACTCCTCCCTTAA-3 0 ) designed to amplify independently of the ACTB methylation status was used to normalize for input DNA. The percentage of methylated alleles was calculated by dividing the HIF-1a/ACTB ratio of a sample by the HIF-1a/ACTB ratio of bisulfite-modified Universal Methylated DNA (Chemicon, Temecula, CA, USA) and multiplying by 100. Quantitative real-time PCR analysis was performed using the ABI PRISM 7300 Sequence Detection System instrument (Applied Biosystems, Foster City, CA, USA). (c) Activation of the HIF-1a promoter under hypoxic conditions was measured in luciferase activity assays 24 h after transfection of cells with luciferase reporter genes linked to the HIF-1a promoter domain (À1163 to þ 117) comprising the wild-type (HIF-1a wt), or the mutated HRE (HIF-1a mut). The HIF-1a promoter region (À1163 to þ 117) was cloned into the basic pGL4 luciferase reporter vector (Promega, Madison, WI, USA). The variant with the mutated HRE was generated using QuickChange SiteDirected Mutagenesis Kit (Stratagene, La Jolla, CA, USA). At 24 h before transfection, 4 Â 10 5 cells were seeded into six-well plates. Promoter constructs were co-transfected with an eGFP reporter construct as transfection and normalization control. At 48 h after transfection, cells were collected, lysed and luciferase activity was measured on an Infinite M200 microplate reader (Tecan, Ma¨nnerdorf, Switzerland). All assays were done in triplicates; mean values ± s.d. are shown. (d) Binding of HIF-1a to the predicted HRE was assessed using NoShift Transcription Factor Assay Kit (Novagen, Madison, WI, USA) as described previously (Koslowski et al., 2009a, b) . Briefly, biotinylated double-stranded oligonucleotides covering the wildtype (5 0 -CACAGACGAGCACGT GAGCGTCGCAGC-3 0 ), the mutated (5 0 -CACAGACGAGCAAAAGAGCGTCGCAGC-3 0 ), or the methylated (5 0 -CACAGAC GAGCACmetGTGAGCGTCGCAGC-3 0 ) HIF-1a HRE were incubated with nuclear extracts of desferroxamine-treated HCT-116 cells. Nonbiotinylated double-stranded oligonucleotides were used as controls. For preparation of nuclear extracts NucBuster Protein Extraction Kit (Novagen) was used. The extract/probe mixtures were transferred to a streptavidin-coated 96-well plate and incubated for 1 h at 37 1C. An antibody specific for HIF-1a (Abcam) was added to the samples and incubated for 1 h at 37 1C. The secondary antibody conjugated with horseradish peroxidase was incubated for 30 min at 37 1C. After final washing, tetramethylbenzidine substrate was added to the samples to develop colorimetric signal before quenching the reaction with 1 N HCl. Sample absorbance was read at 450 nm on a Wallac Victor 2 multilabel counter (Perkin Elmer, Waltham, MA, USA). (e) ChIP was performed with chromatin prepared from PBMCs and HCT-116 cells treated with 5-aza-dC as indicated after exposure to 1% O 2 for 12 h. ChIP assays were performed using the Chromatin Immunoprecipitation (ChIP) Assay Kit (Millipore, Billerica, MA, USA) according to the manufacturer's instructions as described previously (Koslowski et al., 2009a, b) . Soluble chromatin was prepared by sonication followed by immunoclearing. Immunoprecipitation was carried out at 4 1C overnight utilizing an antibody specific for HIF-1a. Following immunoprecipitation, protein A-Sepharose beads and salmon sperm DNA were added. After several rounds of washing, the precipitates were extracted three times with 1% SDS, 0.1% NaHCO 3 . After reversal of cross-linking with 5 M NaCl at 65 1C for 6 h, precipitates were treated with proteinase K, followed by phenol extraction and ethanol precipitation. The purified DNA was analyzed by conventional PCR for the presence of the human HIF-1a promoter fragment À254 to À92, and for the fragment À1633 to À1472 upstream of the promoter. PCR amplification of 1% of the soluble chromatin before immunoprecipitation was used as input control. The HIF-1a promoter region containing the HRE (À254 to À92) and a region upstream of the promoter (À1633 to À1472) as negative control were amplified by PCR following immunoprecipitation with an antibody specific for HIF-1a.
HIF-1a autoregulation M Koslowski et al cells with an unmethylated HRE (Figure 2e ). Taken together, these results suggested positive autoregulation of HIF-1a that is governed by the methylation-sensitive HRE in the HIF-1a promoter.
Positive autoregulation of transcription factors is an important physiological mechanism for maintaining a committed differentiation state during distinct stages of cell lineage and tissue development by reinforcing the formation of high concentrations of several master regulators of cell differentiation, such as MyoD1, GHF1, POUF1 (Pit-1), GATA-1 and NFATc1 (Thayer et al., 1989; Chen et al., 1990 Chen et al., , 1995 McCormick et al., 1990; Yu et al., 2002; Serfling et al., 2006) . In cancer cells, aberrant autoregulation loops initiated by tumorassociated expression of specific cofactors or the loss of repressor proteins, normally preventing binding of the factors to their respective core promoter elements, may promote malignant transformation, as has been reported for c-jun, the first nuclear protooncogene shown to have transactivating properties, c-myb, SP1 and others (Angel et al., 1988; Nicolaides et al., 1991; Kanai et al., 2006) . To our knowledge, however, this is the first time differential methylation of a transcription factors core binding element has been reported to govern its positive autoregulation.
Disorganization of genomic DNA methylation patterns that regulate the normal cellular homeostasis of gene expression is a fundamental hallmark of cancer and contributes to carcinogenesis by mechanisms, such as induction of endogenous retroviral elements, leading to insertional activation of protooncogenes (Jaenisch et al., 1985) , activation of protooncogenes by loss of imprinting (Wainfan and Poirier, 1992; Karpf and Jones, 2002) and induction of chromosomal instability Gaudet et al., 2003) . In fact, loss of global genomic DNA methylation is one of the earliest epigenetic changes detectable in the process of carcinogenesis (Ehrlich, 2002; Esteller, 2008) . In particular for colon cancer, it has been shown that genomic DNA hypomethylation even precedes malignant conversion as it is already apparent in the premalignant lesions of the colon (benign colon polyps) (Goelz et al., 1985; Feinberg, 1988; Feinberg et al., 1988) . On the basis of this knowledge, we extended analysis of the methylation status of the HIF-1a HRE by methylation-specific quantitative PCR assay and bisulfite sequencing to more colon cancer cell lines (Figures 3a and b) . Corresponding to our findings in HCT-116 cells, we detected complete methylation of the HRE CpG dinucleotide in SW48 and HT-29 cells, which was completely reversed after treatment with 5-aza-dC. Unexpectedly, methylation was already lost in untreated SW480 and LoVo cells. Chromatin immunoprecipitation assays showed that HIF-1 was efficiently recruited to the endogenous HIF-1a promoter in untreated hypoxic SW480 and LoVo cells, whereas no recruitment occurred in SW48 and HT-29 cells (Figure 3c ). However, in 5-aza-dC-treated cells HIF-1 was effectively 
HIF-1a autoregulation
M Koslowski et al recruited to the HIF-1a promoter. In line with this, we observed hypoxic induction of HIF-1a transcription only in SW480 and LoVo cells. In SW48 and HT-29 cells, induction of HIF-1a transcription was only detectable following 5-aza-dC treatment ( Figure 3d ). Next, we expanded methylation-specific quantitative PCR analysis to DNA from normal colon and colon cancer tissue samples derived from patients. In all normal tissues, the HRE CpG dinucleotide was completely methylated (Figure 4a ). In 13 of 20 colon cancer samples, in contrast, we detected significant loss of CpG methylation as compared with normal colon specimens. These results were confirmed by bisulfite sequencing of the HIF-1a promoter in selected tissue samples (Figure 4b ). HIF-1 was efficiently recruited to the endogenous HIF-1a promoter in colon cancer samples with hypomethylated HRE, but neither in normal tissues nor in those colon cancer samples with completely methylated HRE (Figure 4c ). Most interestingly, when quantifying HIF-1a mRNA expression in these tissue samples, we found a strong inverse correlation between HIF-1a transcript levels and HRE CpG methylation (Figure 4d ), indicating that a methylationfree HRE in the HIF-1a promoter facilitates positive autoregulation of HIF-1a in colon cancer. Our data introduce tumor-associated CpG demethylation as novel hitherto unknown mechanism at the core of HIF-1a autoregulation in cancer cells. We propose that CpG demthylation implements a permissive state for positive autoregulation of HIF-1a in cancer cells. Thus, cancer cells are endowed with a selective advantage for the cellular adaption to hypoxia and other HIF-1a-mediated effects on malignant cell growth.
In summary, this report provides novel and highly unexpected insight into the complex regulatory network governing HIF-1a activity in cancer and sheds new light on the multifaceted role of tumor-associated CpG demethylation.
